Evidence map›Paper›PMID 41097766›Full record

ReviewCancers2025

Unusual Manifestations of Primary Pancreatic Neoplasia.

Emilia Włoszek, Kamila Krupa, Marta Fudalej, Hanna Miski, Anna M Badowska-Kozakiewicz, Andrzej Deptała

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emilia WłoszekStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0009-0001-8281-853X
Kamila KrupaStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0009-0006-1122-6445
Marta FudalejDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0001-8665-2875
Hanna MiskiStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Anna M Badowska-KozakiewiczDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Andrzej DeptałaDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0003-2640-2043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) represents a malignancy characterized by one of the lowest survival rates; furthermore, at the time of diagnosis, the majority of tumors are deemed unresectable. Consequently, there exists a pressing need to investigate early signs and symptoms, as well as to implement screening protocols for patients at risk of developing PDAC. By doing so, we may enhance the potential for improved treatment outcomes in light of the typically poor prognosis associated with PDAC. A review of recent literature focused on symptoms that manifest prior to the diagnosis of PDAC has been conducted, emphasizing the underlying biological mechanisms and potential screening applications, alongside data pertaining to the influence of these symptoms on prognosis and treatment. Additionally, the roles of pre-existing pain, depression, diabetes mellitus, and paraneoplastic syndromes in treatment and outcomes were scrutinized to ascertain the feasibility of integrating these factors into clinical practice.

Indexed as

depressionearly detectionnew-onset diabetes mellituspain in cancerpancreatic ductal adenocarcinomaparaneoplastic syndrome

Identifiers

PMID41097766
PMCPMC12523438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.